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Abstract
Elevated expression of Eph receptors has long been
correlated with the growth of solid tumors. However,
the functional role of this family of receptor tyrosine
kinases in carcinogenesis and tumor angiogenesis
has not been well characterized. Here we report that
soluble EphA receptors inhibit tumor angiogenesis
and tumor progression in vivo in the RIP-Tag trans-
genic model of vascular endothelial growth factor
(VEGF)–dependent multistage pancreatic islet cell
carcinoma. Soluble EphA receptors delivered either
by a transgene or an osmotic minipump inhibited the
formation of angiogenic islet, a premalignant lesion,
and reduced tumor volume of solid islet cell carcino-
ma. EphA2-Fc or EphA3-Fc treatment resulted in
decreased tumor volume but increased tumor and
endothelial cell apoptosis in vivo. In addition, soluble
EphA receptors inhibited VEGF and BTC tumor cell–
conditioned medium-induced endothelial cell migra-
tion in vitro and VEGF-induced cornea angiogenesis
in vivo. A dominant negative EphA2 mutant in-
hibited—whereas a gain-of-function EphA2 mutant
enhanced—tumor cell– induced endothelial cell migra-
tion, suggesting that EphA2 receptor activation is
required for tumor cell–endothelial cell interaction.
These data provide functional evidence for EphA class
receptor regulation of VEGF-dependent tumor angio-
genesis, suggesting that the EphA signaling pathway
may represent an attractive novel target for antiangio-
genic therapy in cancer.
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Introduction
Traditional preclinical studies testing the efficacy of a com-
pound in a tumor model usually involve subcutaneous or
intravenous injection of human tumor cells into immunode-
ficient mice. Although these ‘‘proof-of-principle’’ experi-
ments provide valuable information in an in vivo system,
recent clinical trials of antiangiogenic agents, such as matrix
metalloproteinase (MMP) inhibitors, revealed that these
ectopic graft models are inadequate and do not recapitulate
host–tumor interactions [1,2]. Thus, it is critical to evaluate
antiangiogenic agents in an animal model where tumors arise
from normal cells in their natural tissue microenvironments and
progress through multiple stages, as does human cancer.
One attractive target for antiangiogenic cancer therapy is
the Eph family of receptor tyrosine kinases. The Eph family of
RTKs and their ligands, known as ephrins, directs a variety
of biologic processes during embryogenesis [3–6]. The role of
this family of RTKs in cancer is complex and has just begun to
be investigated (reviewed in Refs. [5,7]). Aside from a potential
role in tumor cells, recent studies suggest that class A Eph
RTKs are also essential in regulating tumor angiogenesis.
First, a survey of expression patterns of Eph molecules in
tumor vasculature revealed that the ephrin-A1 and EphA2
ligand–receptor pair is consistently expressed in endothelial
cells of tumor-associated vessels in a variety of tumors, includ-
ing tumor xenografs (MDA-MB-435 human breast cancer and
KS1767 human Kaposi’s sarcoma) and human tumor speci-
mens (breast cancer, lung anaplastic adenocarcinoma, squa-
mous carcinoma, gastric cancer, colon carcinoma, and kidney
clear cell carcinoma) [8]. Second, ephrin-A1 and EphA2 were
also found to be expressed in tumor endothelial cells in two
murine models that are angiogenesis-dependent: the RIP-Tag
islet carcinoma model and 4T1 transplantable metastatic
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mammary carcinoma model [9]. Finally, we have shown that
local administration of soluble EphA2-Fc chimeric receptors
could inhibit tumor growth and angiogenesis in a subcuta-
neous graft of 4T1 mammary carcinoma cells, a model that is
involved in transplantation of malignant tumor or tumor cells
into an ectopic site in a recipient mouse [9].
Although the above studies support a role of class A Eph
molecules in tumor progression, the functional relevance of
the above studies to tumors spontaneously arisen in an
endogenous environment remains to be determined. In this
report, we studied the effect of soluble EphA2 and EphA3
receptor Fc fusion proteins (EphA2-Fc/EphA3-Fc) on pan-
creatic islet cell carcinoma in the RIP-Tag transgenic mice. In
this model, tumors arise spontaneously in an endogenous
environment and the development of tumors involves multi-
ple stages, progressing from morphologically normal islets,
hyperplasia, angiogenic dysplasia, to invasive islet cell car-
cinoma (reviewed in Refs. [10–12]). Here we report that local
or systemic delivery of soluble EphA receptors significantly
inhibits the formation of angiogenic islets and reduces tumor
volume. Furthermore, studies of interactions between RIP-
Tag tumor cells and endothelial cells in vitro indicate that
EphA2 receptor and vascular endothelial growth factor
(VEGF) signaling pathways are required for endothelial cell
activation by tumor cells. Thus, blockade of EphA signaling
inhibits tumor-induced endothelial cell migration and repre-
sents a testable therapeutic approach against cancer.
Materials and Methods
Soluble EphA-Fc Receptors
The EphA2-Fc soluble receptor cDNA construct contain-
ing the extracellular domain of EphA2 (a.a. 1–495) and Fc
portion of IgG1 was provided by Dr. N. Gale (Regeneron,
Tarrytown, NY) and subcloned into episomal expression
vector pCEP4 (Invitrogen, San Diego, CA). Recombinant
EphA2-Fc proteins were either purified from a culture super-
natant of stable 293T clones expressing these factors using
protein A Sepharose column, or purchased from R&D Sys-
tems (Minneapolis, MN). Recombinant EphA3-Fc protein
was provided by Immunex (Seattle, WA). To inhibit binding
to Fc receptors and complements, the following amino acids
in human IgG1 lambda chain Fc region were mutated in the
EphA3-Fc construct: L264A, L265E, and G267A.
Mouse Strains and Maintenance
RIP1-Tag2 C57BL/6 mice (generously provided by Dr.
Doug Hanahan, University of California at San Francisco)
and wild-type C57BL/6 mice were maintained in accordance
with AAALAC and Vanderbilt University guidelines. RIP1-
Tag2 transgenic animals were maintained on a sucrose-
enriched diet (Teklad Test Diets, Madison, WI) and 4%
glucose water. Animals positive for the RIP-Tag transgene
were identified by polymerase chain reaction (PCR) analysis
of genomic DNA from tail biopsy using the following primers:
5V-GGACAAACCACAACTAGAATG-3V and 5V-CAGAGCA-
GAATTGTGGAGTGG-3V.
EcoRI–NotI fragment containing EphA2-Fc chimeric
fusion cDNA (provided by Dr. Nick Gale; Regeneron)
was blunted and subcloned into the ClaI site of transgenic
RIP-7 vector (provided by Dr. Hanahan, University of
California at San Francisco). The linearized fragment
encompassing the tissue-specific transcription unit was
microinjected into the pronuclei of C57BL/6DBA/2
zygotes. Transgenic founders were identified by genomic
Southern blot and PCR analyses using the following primers:
5V-ACGCTGACCACACGGTACGT-3V and 5V-AGCCCCA-
CATGAACTATACC-3V. RIP-EphA2-Fc transgenic mice were
backcrossed to C57BL/6 for three generations before inter-
crossing with RIP-Tag mice.
Pharmacologic Intervention
RIP1-Tag2 transgenic mice on C57BL/6 background
were used in these studies. Animals were treated either
from 8 to 10 weeks of age, or from 10 to 12 weeks of age.
Five hundred micrograms of soluble EphA2-Fc, EphA3-Fc,
or Fc control (IgG) was loaded into 2-week osmotic pumps
(model 2002; Alzet, Osmotic Pumps, Cupertino, CA), which
were implanted intraperitoneally. Animals were monitored
three times a week and sera were collected for enzyme-
linked immunosorbent assay (ELISA) to determine the
serum concentration of Fc proteins.
Assessment of Angiogenic Islets and Tumor Volume
Pancreatic islets were isolated by retrograde perfusion
with collagenase P as described [13]. Angiogenic islets were
identified as those that exhibited a reddish patch in a white
nodular background and enumerated under the dissecting
microscope. The visual scoring was confirmed by histology.
Tumors were microdissected from freshly excised pan-
creases. Tumors (>1 mm in diameter) were measured with
calipers, and tumor volumes were calculated as described
[volume = 0.52(width)2 length] [13].
ELISA for Fc Proteins
Serum samples were collected before osmotic pump
implantation and 4, 7, 10, and 14 days after implantation
for the detection of EphA2-Fc, EphA3-Fc, and control IgG
levels. In brief, ELISA plates were coated overnight at 4jC
with serum samples in serial dilutions (1:20, 1:40, and 1:60)
in coating buffer (34.4 mM sodium bicarbonate, 15 mM
sodium carbonate, and 3 mM sodium azide). Standards were
prepared by diluting IgG protein (Sigma, St. Louis, MO) with
coating buffer (from 0.01 to 100 ng/ml). After washing with
PBS containing 0.1% Tween 20, nonspecific binding was
blocked by PBS containing 10% FBS for 1 hour at room
temperature. Samples were then incubated with affinity-
purified biotinylated goat antihuman IgG (1 Ag/ml) antibodies
(crossreactivity with mouse IgG <1%; Vector Laboratories,
Burlingame, CA) at room temperature for 2 hours, followed
by incubation with avidin conjugated alkaline phosphatase
(1:400 dilution; Sigma) for 30 min. Plates were developed
using TMB as substrates (Sigma). The color reaction was
stopped by 1 M HCl and the OD was measured at 450 nm
using a microplate reader and Delta3 software.
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Histologic Analyses
Pancreatic tissue was fixed in 10% neutral-buffered for-
malin (Fisher) overnight at 4jC, subjected to graded dehy-
dration and paraffin embedding, and 7-Am sections were
prepared for immunohistochemistry. For Fc protein staining,
samples were blocked for 1 h in PBS containing 5% sheep
Figure 1. Inhibition of angiogenic islet formation and tumor volume in RIP-EphA2-Fc/RIP-Tag transgenic mice. (A) RIP-EphA2-Fc transgenic mice express soluble
EphA2-Fc in pancreatic islets. Total pancreatic lysates from either transgenic RIP-EphA2-Fc mice or control wild-type littermates were immunoprecipitated by
protein A/G beads and subjected to Western blot analysis using a goat antihuman IgG antibody (top panel). Islet-specific expression of soluble EphA2-Fc was
confirmed by immunohistochemistry (bottom panel). EphA2-Fc: purified recombinant protein used as positive control. Arrows indicate pancreatic islets.
(B) Inhibition of angiogenic islet formation in RIP-EphA2-Fc/RIP-Tag double transgenic mice. Pancreatic islets were isolated from 10-week–old RIP-EphA2-Fc/
RIP-Tag double transgenic mice or wild-type control littermates by retrograde perfusion with collagenase P. Angiogenic islets were identified as those exhibiting a
reddish patch in a white nodular background and counted. (C) Inhibition of tumor volume in RIP-EphA2-Fc/RIP-Tag double transgenic mice. Pancreatic islet tumors
were microdissected from freshly excised pancreases from 12-week–old mice. Tumors (>1 mm in diameter) were measured with calipers and tumor volumes were
calculated as described in Materials and Methods section. Statistical analysis was performed by two-tailed, unpaired, Student’s t-test. *P < .01; **P < .05 vs control.
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serum (Sigma) and incubated with affinity purified biotiny-
lated goat antihuman IgG antibodies (1:100 dilution; Vector
Laboratories) overnight at 4jC. For VEGFR2 (Flk-1)/TUNEL
immunofluorescence double staining, sections were pre-
treated with proteinase K (Dako, Cytomation, Denmark) for
10 minutes at 37jC, blocked with PBS/5% sheep serum for
1 hour, and incubated with polyclonal rabbit anti-VEGFR
antibodies T014 (5 Ag/ml) (kindly provided by Dr. R. Brekken,
UT Southwest) overnight, followed by secondary biotinylated
anti-rabbit IgG (Pharmingen, San Diego, CA) and streptavi-
din-conjugated Alexa 488 flourochrome (Molecular Probes,
Eugene, OR). Sections were then subjected to TUNEL assay
using an ApopTag Red in situ apoptosis detection kit (Inter-
gen, Purchase, NY) and counterstained with DAPI (0.05 Ag/
ml in PBS; Sigma) to visualize nuclei. Apoptotic cells were
quantified by numerating rhodamine-stained nuclei. Percent-
age of total apoptosis was calculated as the number of
rhodamine-stained nuclei/total number of DAPI-stained
nuclei, using Scion Image software. Apoptotic endothelial
cells were determined by cells stained positive for both
TUNEL (red) and VEGFR (green) (double positive cells,
yellow in overlay image). Percentage of apoptotic cells was
then calculated as the number of double positive cells/total
number of DAPI-stained nuclei. Experiments were repeated
three times and results were pooled. Statistical analysis was
performed using the two-tailed, paired Student’s t-test.
Endothelial and bTC Cell Culture
The h islet carcinoma cell line (hTC) derived fromRIP-Tag
mice (provided by Dr. Hanahan) were maintained in DMEM/
30% fetal bovine serum. Human primary umbilical endothelial
cells (HUVECs) and bovine primary pulmonary microvascu-
lar endothelial cells (BPMECs) were purchased from Clo-
netics (Walkersville, MD) and Vec Technologies (Rensselaer,
NY), respectively, and maintained in 10-cm dishes coated
with 0.1% gelatin in complete EBMmedium (Clonetics). Cells
were used up to six passages. For tumor-conditioned
medium, hTCs were grown to 80% confluency, washed with
PBS, and incubated inminimal volume (3ml for a 10-cm dish)
of low serum medium (DMEM/2% FBS) overnight. Condi-
tioned medium was collected after 24 hours of incubation.
Migration Assays
Endothelial cell migration was determined by wound
closure assay as described previously [14]. Briefly, replicate
circular ‘‘wounds’’ were generated in confluent HUVEC cell
monolayers using a silicon-tipped drill press. Endothelial
cells were then treated with tumor cell–conditioned medium
in the presence or absence of 5 Ag/ml EphA2-Fc or 10 Ag/ml
neutralizing antibodies against VEGF. Residual fractional
‘‘wound’’ areas were measured following 0, 4, 8, and 12
hours using Bioquant software. A ‘‘wound’’ completely
closed is referred to as 100% closure. Experiments were
repeated three times and results were pooled. Statistical
analysis was performed by Student’s t-test.
Mouse Corneal Angiogenesis Assay
Hydron pellets incorporating sucralfate with recombinant
human VEGF (160 ng/pellet; R&D Systems) were made as
described [15]. Pellets were surgically implanted into cor-
neal stromal micropockets created 1 mm medial to the
lateral corneal limbus of C57L male mice (7 weeks old).
The mice were treated systemically by daily intraperitoneal
injection of 400 Ag of IgG1 control (Sigma) or EphA3-Fc
(Immunex), beginning 1 day prior to implantation. At day 5,
corneal angiogenic responses were photographed using an
Insight Spot digital camera under Leico dissection micro-
scope. The percentage of vascularized area/total corneal
image was calculated using the Spot software. Each value
is the meanFSEM of six corneas for each condition. Stat-
istical analysis was performed using the two-tailed, paired
Student’s t-test (P < .05).
Co-culture Migration Assay
EphA2-Neu was generated by substituting the transmem-
brane domain (a.a. 496–516) with that from the oncogenic
neu (VTFIIATVEGVLLFLILVVVVGILI) [16]. The myc-tagged
dominant negative EphA2 cytoplasmic domain truncation
mutant (EphA2-DC) was generated by PCR amplification of
the extracellular and transmembrane domains of EphA2
(a.a. 1–521). COS-1 cells were transfected with 10 Ag of
pECE-EphA2WT or pECE-EphA2Neu, or mock-transfected
using Lipofectin. EphA2 was immunoprecipitated and sub-
jected to SDS-PAGE and Western blotting using an anti-
phosphotyrosine (PY) antibody. To test cytoplasmic domain
truncation mutant of EphA2, COS-7 cells were transiently
transfected with 10 Ag of pcDNA3-EphA2-DC or empty
vector pcDNA3 by DEAE dextran method. Two days after
transfection, cells were starved in DMEM without serum
followed by stimulation of 1 Ag/ml ephrin-A1 for 15 minutes.
Endogenous EphA2 receptor was immunoprecipitated and
subjected to SDS-PAGE and Western blotting using anti-PY
antibodies (pY99 and pY20; Santa Cruz Biotechnology,
Figure 2. Osmotic minipump delivery of soluble EphA receptors inhibits angiogenic islet formation and tumor volume in RIP-Tag mice. (A) Serum concentration of
Fc proteins. Serum samples were collected before osmotic pump implantation and 4, 7, 10, and 14 days postimplantation for the detection of soluble EphA2-Fc
( ), EphA3-Fc ( X___), and control IgG levels ( l___) in the circulation. Serum concentration of these Fc chimeric proteins was determined by ELISA using a goat
antihuman IgG antibody. (B) Inhibition of angiogenic islet formation by 2-week treatment of soluble EphA receptors. An osmotic minipump containing 500 lg of
soluble EphA receptor or Fc control protein, IgG, was implanted intraperitoneally in RIP-Tag mice at 8 weeks of age. Angiogenic islets were isolated from treated or
control mice at 10 weeks of age and enumerated. EphA-Fc, EphA2-Fc, or EphA3-Fc. (C) Soluble EphA receptors inhibited tumor volume in RIP-Tag mice. An
osmotic minipump containing 500 lg of soluble EphA receptor or Fc control protein, IgG, was implanted intraperitoneally in RIP-Tag mice at 10 weeks of age. Islet
tumors were isolated from treated or control mice at 12 weeks of age and tumor volumes were calculated. (D) Soluble EphA receptor inhibited tyrosine
phosphorylation of endogenous EphA2 receptor in islet tumor. Endogenous EphA2 from IgG or soluble EphA receptor – treated tumors (1 mg of protein lysates)
were immunoprecipitated by an anti-EphA2 antibody and subjected to Western blot analysis using antiphosphorylated tyrosine antibodies. Statistical analysis was
performed by two-tailed, unpaired, Student’s t-test. *P < .01 vs control.
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Santa Cruz, CA). Blots were stripped and reprobed for
EphA2 expression to ensure equal loading (D7; Upstate
Biotechnology, Lake Placid, NY).
Prior to co-culture, 0.5  106 bovine pulmonary micro-
vascular endothelial cells (BPMECs) were seeded in 6
well dishes and transfected with 1 Ag of pGABE control
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GFP vector (Mock), wild-type EphA2 (WT), EphA2-DC
(DC), or EphA2-Neu (Neu) using the Lipofectamine 2000
reagent. Transfection efficiency was estimated to be
approximately 50%, judging by GFP expression in control
plates. Overexpression of EphA2-Neu and EphA2-DC
mutants was confirmed by immunoblot analysis using
anti-EphA2 (Santa Cruz Biotechnology or Upstate Biotech-
nology) and anti-myc (Pharmingen) antibodies, respec-
tively. For activity assay, BPMECs expressing wild-type
EphA2, EphA2-Neu, or EphA2-DC were stimulated with
1 Ag/ml soluble ephrin-A1-Fc, EphA2-immunoprecipitated,
and subjected to PY blot analysis.
BPMEC/hTC coculture migration assays were adapted
from a modified Boyden chamber assay and performed as
described [9]. Briefly, hTCs were labeled with FITC ovalbu-
min and grown on the underside of the filter (pore size 8 Am).
BPMECs labeled with Texas Red ovalbumin were added to
upper transwell chambers. After 5 hours, cells were
removed from the upper surface of the transwell filter using
a cotton swab, and endothelial cell density on the lower
surface of the filter was quantified by counting red fluores-
cent pixels using Scion Image software analysis. Data are
representations of eight independent samples per condition
with standard deviation, and statistical significance was
determined by two-tailed, paired Student’s t-test.
Results
Inhibition of Tumor Angiogenesis and Tumor Growth in
RIP-EphA2-Fc/RIP-Tag Double Transgenic Mice
To investigate the role of class A Eph receptors and
ephrin ligands in multistage carcinogenesis in vivo, we
utilized the RIP-Tag transgenic mouse model of pancreatic
islet cell carcinoma, in which the rat insulin promoter drives
expression of the SV40 large T antigen oncogene in the
h-cells of pancreatic islets [10–12]. These animals undergo
tumorigenesis in a reproducible series of stages, including
hyperplasia, angiogenic dysplasia, and invasive carcinoma,
one of which involves the initiation of angiogenesis. Ephrin-
A1 ligand is overexpressed in RIP-Tag islet cell carcinomas,
both in tumor and endothelial cells, whereas EphA2 receptor
is expressed in tumor-associated vasculature, suggesting a
proangiogenic function for this ligand–receptor pair [9]. As a
first step to determine whether blockade of EphA receptor
function could affect multistage tumorigenesis, we generated
RIP-EphA2-Fc transgenic mice to deliver soluble EphA2
receptor locally in the pancreatic islet, using the same rat
insulin promoter as in RIP-Tag mice. As shown in Figure 1A,
EphA2-Fc proteins were expressed in the pancreatic islet in
transgenic mice, as judged by Western blot analysis and
immunohistochemistry. The RIP-EphA2-Fc transgenic mice
developed and bred normally in the pathogen-free animal
facility and there were no significant changes in the number
and morphology of pancreatic islets (data not shown)
between RIP-EphA2-Fc transgenic animals and control non-
transgenic littermates, suggesting that soluble EphA receptor
does not affect normal islet development.
The RIP-EphA2-Fc transgenic mice were backcrossed
into C57BL/6 background for three generations, and inter-
crossed with RIP-Tag transgenic mice to determine the
effect of soluble EphA2 receptor on tumor progression in
vivo. In the RIP-Tag model, islets expressing SV40 Tag
oncogene are morphologically normal until about 4 weeks
of age. Hyperplastic islets then begin to develop as white
nodules with hyperproliferation and characteristics of carci-
noma in situ. Angiogenic islets arise from hyperplastic nod-
ules at approximately 8 weeks of age as white nodules with
reddish patches, characterized by endothelial sprouting,
microhemorrhaging, and the ability to elicit an angiogenic
response in vitro. Highly vascularized small solid tumors
emerge at 10 weeks and progress to merge into a few, large,
invasive carcinomas (12–14 weeks).
Two specific stages of tumorigenesis were examined in
RIP-Tag mice: the formation of angiogenic islets/small
tumors at 10 weeks of age, and tumor volume of highly
angiogenic islet cell carcinoma at 12 weeks of age. As shown
in Figure 1B, at 10 weeks of age, there is two-fold decrease
in the number of angiogenic islets and small tumors in RIP-
EphA2-Fc/RIP-Tag double transgenic mice, compared to
RIP-Tag single transgenic littermate controls. By 12 weeks
of age, control RIP-Tag mice have developed several large
tumors. In contrast, the tumors in the RIP-Tag/RIP-EphA2-
Fc double transgenic mice are much smaller, with a two-fold
reduction in average tumor volume (Figure 1C). The num-
bers of tumors in dual RIP-Tag/RIP-EphA2-Fc and in control
RIP-Tag mice did not vary significantly (7.2F 2.5 in RIP-Tag
controls compared to 8.6F1.8 in dual transgenic mice).
Thus, the phenotypes in double transgenic mice at 12 weeks
resemble those at 10 to 11 weeks in RIP-Tag control mice,
reflecting the inhibition of small tumor growth and merging
into large tumors by soluble EphA2-Fc receptors. There is no
significant morphologic change in the tumor section, except
that apoptosis levels were increased in tumors from dual
transgenic mice (Figure 3). Taken together, these data
suggest that soluble EphA receptors inhibit angiogenic islet
formation and small tumor progression in large tumors,
although they do not block tumor formation entirely.
Osmotic Pump Delivery of Soluble EphA Receptors
Inhibited Formation of Angiogenic Premalignant
Lesions and Islet Carcinoma Progression in RIP-Tag Mice
Encouraged by the results in RIP-EphA2-Fc/RIP-Tag
double transgenic mice, we designed a study to assess
the effects of exogenously delivered soluble EphA recep-
tors in RIP-Tag mice at two distinct stages of pancreatic
islet carcinogenesis. Two different forms of EphA soluble
receptors, EphA2-Fc and EphA3-Fc, were used because
mutations in the Fc portion of the EphA3-Fc chimeric
protein block interaction with Fc receptors and complement
[24–26]. Both EphA2-Fc and EphA3-Fc inhibited endoge-
nous endothelial EphA receptor activation in response to
ephrin stimulation and ephrin-A1–induced corneal angio-
genesis (data not shown). An osmotic minipump was used
to deliver 500 Ag of soluble receptors or Fc control protein
(IgG) over a 2-week period, as prior studies showed that in
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comparison to bolus intraperitoneal injection, continuous
administration of angiogenesis inhibitors by an osmotic
pump implanted intraperitoneally resulted in a decrease
of the required dosage and improved the effectiveness of
therapy [17]. As shown in Figure 2A, soluble EphA recep-
tors administered continuously through mini-osmotic pump
Figure 3. Soluble EphA-Fc receptors enhance tumor cell and endothelial cell apoptosis in RIP-Tag islet tumors. Apoptosis in RIP-Tag tumors was assessed by
dual immunofluorescence staining for VEGFR2 (Flk-1) and TUNEL assay. (A) More TUNEL-positive nuclei (red) were observed in tumors treated with soluble
EphA-Fc receptor than those treated with control IgG. Total nuclei in tumor sections were visualized by DAPI staining (blue), and endothelial cells were stained by
anti –Flk-1 antibodies (green). Endothelial cell apoptosis was shown as double positive for TUNEL and VEGFR2 (yellow in overlaid insert). (B) Total apoptosis in
tumor in RIP-Tag/RIP-EphA2-Fc double transgenic mice or in RIP-Tag single transgenic littermates was determined by quantifying the number of pixels in TUNEL-
positive nuclei relative to the number of DAPI pixels (total nuclei). The level of endothelial apoptosis and the level of tumor cell apoptosis were determined by the
number of pixels of double positive cells (yellow)/the number of DAPI pixels, and the number of pixels of total TUNEL-positive nuclei (red)double positive cells
(yellow)/number of DAPI pixels, respectively. (C) The levels of endothelial and tumor cell apoptosis in RIP-Tag mice treated with soluble EphA receptor or control
IgG were calculated as described in (B) (n = 5 independent samples/condition for in vivo analysis). Statistical analysis was performed using the two-tailed, paired
Student’s t-test. *P < .01; **P < .05 vs control.
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maintain systemic serum concentrations of 50 to 150 ng/ml
for the duration of administration.
In the prevention trial, an osmotic pump containing 500 Ag
of soluble EphA receptor or control IgG protein was implanted
into 8-week–old RIP-Tag mice to inhibit the angiogenic
switch before the initial formation of solid tumors. Two weeks
later (10-week–oldmice), angiogenic islets and small tumors
were isolated by retrograde infusion of collagenase P and
enumerated. Administration of either EphA2-Fc or EphA3-Fc
significantly reduced the incidence of angiogenic islet and
small tumor formation, compared to animals treated
with control IgG (Figure 2B). In the intervention trial,
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treatment of the RIP-Tag mice began at 10 weeks of age
when every mouse developed a few small but highly vascu-
larized solid tumors, and ended 2 weeks later. Consistent
with data in RIP-Tag/RIP-EphA2-Fc double transgenic mice,
treatment of RIP-Tag mice with soluble EphA-Fc proteins
resulted in a two-fold decrease in tumor volume, although
there was an increase in small tumor numbers (4.70F1.4 in
IgG-treated mice vs 8.09F3.5 in EphA3-Fc–treated mice)
(Figure 2C) compared to mice treated with Fc control, IgG.
Soluble EphA receptor treatment also resulted in significantly
reduced tyrosine phosphorylation of endogenous EphA2 in
tumors, suggesting that these soluble receptors disrupt
EphA2 signaling in vivo (Figure 2D). Taken together, these
results suggest that soluble EphA receptors inhibit angio-
genic switch and tumor progression in vivo.
Treatment with Soluble EphA Receptors Resulted
in Increased Apoptosis in Both Tumor Cells
and Tumor Endothelium In Vivo
Because our prior studies showed that soluble EphA
receptor reduced vessel density in 4T1 mammary tumor
grafts [9], we investigated whether similar changes occur in
islet cell carcinoma in RIP-Tag mice between mice treated
with soluble EphA receptors and those treated with control
proteins. Interestingly, soluble EphA2 receptors did not
cause significant changes in microvessel density in islet
tumor (data not shown). It has been recently recognized that
during tumor progression under antiangiogenic therapy,
microvessel density can decrease, increase, or remain
unchanged, depending on the relative rates of cell death
between tumor cells and tumor endothelium in a given tumor
[18]. Accordingly, we measured the apoptosis levels of tumor
and endothelial cells simultaneously by dual staining of
TUNEL-positive nuclei and an endothelial cell –specific
marker, Flk-1 (VEGF receptor 2). As shown in Figure 3, both
tumor cells and endothelial cells within tumors treated with
EphA2-Fc or EphA3-Fc displayed increased levels of
TUNEL-positive nuclei relative to those of control IgG-treated
tumors. Thus, it is likely that in treated 4T1 mouse mammary
carcinomas, capillary dropout exceeds tumor cell death so
that vessel density decreases, whereas in treated islet
carcinomas, dropout rates of capillaries and tumor cells are
similar, resulting in unaltered microvascular density.
Because hTCs do not express significant levels of EphA2
receptor and soluble EphA2-Fc do not affect the growth or
apoptosis in cultured tumor cells (data not shown), increased
tumor cell apoptosis is likely due to diminished blood supply
in the treated tumor.
Soluble EphA Receptors Block Tumor Cell–Conditioned
Medium- and VEGF-Induced Angiogenic Responses
Based on our previous studies demonstrating that ephrin-
A1 ligands and EphA2 receptors are expressed complemen-
tarily on tumor cells and vascular endothelial cells [9], we
hypothesize that ephrin-A1 expressed on the tumor cells
recruits blood vessels through activation of endothelial
EphA2 receptors. However, because ephrin ligands are
membrane-bound and soluble monomeric ligands are not
functional [19–21], it is not clear how tumor cells could
stimulate an angiogenic response from vessels that are not
in direct contact with the tumor. Bergers et al. [22] reported
that islet carcinoma expresses VEGF, and blockade of the
VEGF receptor tyrosine kinase by the chemical inhibitor
SU5416 inhibits angiogenic islet formation and tumor burden
in RIP-Tag mice, suggesting that VEGF is a long-range
angiogenic signal produced by the islet tumor cells.
As a first step to dissect the mechanism of soluble EphA
receptor–mediated inhibition of tumor angiogenesis, we
tested whether soluble EphA receptor can block tumor cell
(hTC)–conditioned medium-induced endothelial cell migra-
tion. As shown in Figure 4A, hTC-conditioned medium
induced HUVEC migration, and this response was blocked
by either VEGF-neutralizing antibodies or soluble EphA2-Fc,
suggesting that soluble EphA2-Fc receptor can block VEGF-
induced angiogenic response. Consistent with this observa-
tion, hTC-conditioned medium induced the phosphorylation
of EphA2 receptor (Figure 4B). To further investigate
whether soluble EphA receptors administered systemically
can inhibit VEGF-induced angiogenesis in vivo, hydron
pellets impregnated with VEGF were surgically implanted
into mouse corneal stromal micropockets, and mice were
treated daily for 5 days with either 400 Ag of control IgG or
soluble EphA3-Fc receptors by intraperitoneal injection.
Treatment with soluble EphA3-Fc receptors significantly
inhibited VEGF-induced corneal angiogenesis (Figure 4C).
These data, together with the fact that soluble EphA
receptors inhibit VEGF-dependent islet tumor progression,
suggest an essential role for EphA receptor function in
VEGF-dependent angiogenesis.
EphA2 Receptor Activity Mediates Cellular Interactions
between Tumor and Endothelial Cells
To investigate whether it is the EphA2 receptor specif-
ically, rather than other members of the EphA family, that
plays a role in hTC-induced endothelial cell migration, we
utilized a dominant negative form of EphA2 cytoplasmic
Figure 4. Soluble EphA receptors inhibit bTC-conditioned medium and VEGF-induced angiogenic responses. (A) Soluble EphA2-Fc inhibits tumor cell – conditioned
medium and VEGF-induced endothelial cell migration. Endothelial cell migration was determined by wound closure assay. Replicate circular ‘‘wounds’’ were
generated in confluent HUVEC monolayers, and treated with bTC condition medium in the presence of anti-VEGF neutralizing antibodies or soluble EphA2-Fc.
Residual fractional ‘‘wound’’ areas were measured following a time course. Medium: DMEM/2% FBS. (B) Tumor cell conditioned medium induces phosphorylation
of EphA2 receptor. HUVECs were serum-starved and stimulated with bTC-conditioned media (bTC-CM) or ephrin-A1 at indicated times. Cell lysates were
immunoprecipitated with an anti-EphA2 antibody and subjected to Western blot analysis using anti-PY antibodies pY99 and pY20. (C) Systemic administration of
soluble EphA3-Fc inhibits VEGF-induced mouse corneal angiogenesis. Hydron/sucralfate pellet impregnated with rhVEGF (160 ng/pellet) was implanted into
mouse cornea as described in Materials and Methods section. Mice were treated systemically by daily intraperitoneal injection of 400 lg of EphA3-Fc (solid bar) or
Fc control protein, IgG1 (shaded bar), beginning 1 day prior to implantation. The percentage of vascularized area was determined by the number of blood vessel
pixel/whole corneal area using Spot software (n = 6 per experimental group). Statistical analysis was performed using the two-tailed, paired Student’s t-test.
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domain truncation mutant (EphA2-DC) and an gain-of-
function EphA2 mutant (EphA2-Neu) that is autophosphory-
lated in the absence of ligand stimulation (Figure 5A). Micro-
vascular endothelial cells were transfected with plasmids
expressing either wild-type EphA2, EphA2-Neu, EphA2-
DC, or control pGABE, and approximately 50% of cells were
transfected judging by GFP expression. Western blot anal-
ysis shows that mutant EphA2 proteins are overexpressed,
compared with endogenous endothelial EphA2 in control
cells (Figure 5B). The transfected cells were then tested for
the ability to migrate toward hTCs in a coculture assay.
Endothelial cells expressing EphA2-NeuTM showed a sig-
nificant increase in migration to hTCs, compared to those
transfected with control pGABE. In contrast, expression of
EphA2-DC resulted in a significant decrease in migration
toward hTCs compared to controls (Figure 5C). These data
Figure 5. Inhibition of EphA2 receptor activation blocks tumor cell – induced endothelial cell migration. (A) Expression of EphA2-DC inhibits, and EphA2-Neu
enhances, phosphorylation of EphA2 receptor. EphA2 was immunoprecipitated from transfected COS cells and probed for PY, and EphA2 levels were assessed by
probing for EphA2 expression. (B) Primary BPMECs were transfected with wild-type (WT) EphA2, EphA2-DC (DC), or EphA2-Neu (Neu), and the expression of
wild-type and EphA2 mutant proteins was confirmed by Western blot analysis using antibodies against myc (1:500), EphA2 (1:500), or tubulin (1:1000). (C)
Transfected BPMECs were tested for their ability to migrate to bTCs in a tumor cell –endothelial cell coculture assay as described in Materials and Methods
section. Statistical analysis was performed using the two-tailed, paired Student’s t-test. *P < .01 EphA2-DC or EphA2-Neu vs control.
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suggest that the EphA2 receptor mediates the angiogenic
response initiated by tumors at the level of endothelial cell
migration, providing further support for a proangiogenic role
for EphA2 receptors in tumor progression.
Discussion
An elevated expression of Eph receptors has long been
correlated with the growth of solid tumors. However, the
functional role of this family of receptor tyrosine kinases in
carcinogenesis and tumor angiogenesis has just begun to
be investigated. In particular, expression of ephrin-A1
ligand and EphA2 receptor has recently been shown in a
number of human cancers and tumor vasculature [8]. We
previously reported the expression of this pair of ligand–
receptor in the vasculature of two types of murine cancers,
and that blocking EphA receptor activation inhibits tumor
angiogenesis in a vascular window assay and a subcuta-
neous graft model of 4T1 mammary carcinoma cells [9].
Work presented in this manuscript advanced our previous
findings in several respects. First, this report investigated
the function of EphA receptor tyrosine kinases in an in vivo
tumor model (RIP-Tag transgenic mice), where tumors
arise in an endogenous environment and tumor develop-
ment is multistage. Thus, we show that soluble EphA-Fc
receptors not only inhibited tumor growth and decreased
tumor volume, but also had a negative effect on pretumor
lesions, the angiogenic islets. Second, although there are
many differences between 4T1 breast cancer and islet cell
carcinoma, the fact that soluble EphA receptor inhibited
both types of tumor suggests that tumor endothelium is a
common target of EphA-Fc proteins and that inhibition of
tumor angiogenesis is a general mechanism of suppress-
ing tumor progression by soluble EphA receptors. Third,
instead of in vitro treatment and local delivery of soluble
receptors in our previous studies, inhibition of tumor pro-
gression through a systemic and efficient method of deliv-
ering soluble EphA proteins through an osmotic pump
indicates a possible relevance for EphA targeting in clinical
cancer therapeutics. Finally, using a dominant negative
form of EphA2 cytoplasmic domain truncation mutant
(EphA2-DC) and a gain-of-function EphA2 mutant (EphA2-
Neu), we provided evidence that tumor cell– induced endo-
thelial cell migration is, at least in part, through EphA2
receptor activation.
What is the mechanism of soluble EphA receptor–
mediated inhibition of tumor progression in vivo? The use
of Fc chimeric fusion protein raises the possibility that the
binding of EphA2-Fc or EphA3-Fc to ephrin-A1 on tumor
cells may initiate complement and/or Fc receptor–mediated
cytotoxicity and clearance of tumor cells. We do not favor this
hypothesis. The EphA3-Fc fusion protein, which contains
mutations in the Fc region that inhibit interactions with
complement and Fc receptor, produces effects comparable
to EphA2-Fc on angiogenic islet formation and tumor vol-
ume. Furthermore, our data derived from RIP-EphA2-Fc/
RIP-Tag double transgenic mice, in which soluble EphA2-Fc
is expressed as a part of the host genome, yielded similar
results as exogenously delivered EphA2-Fc. These data
suggest that the effect is due to blocking of endogenous
class A Eph ligand– receptor interactions rather than
immune-mediated clearance of ephrin-A1 expressing carci-
noma or endothelial cells.
Given recent reports of reverse signaling through ephrin
ligands upon stimulation with Eph receptors, it is also possi-
ble that soluble EphA-Fc receptors could initiate ephrin-
mediated reverse signaling in ephrin-A1 expressing tumor
cells and/or endothelial cells. Although we cannot rule out the
modulation of ephrin-A signaling by treatment with soluble
Eph receptors, soluble EphA receptor stimulation alone does
not induce angiogenesis in the mouse cornea, nor does it
alter endothelial cell migration, sprouting, proliferation,
or apoptosis (data not shown). Moreover, reduced phospho-
rylation of EphA2 receptor in endothelial cells by overexpres-
sion of a EphA2-DC mutant (Figure 5) mimics the inhibitory
effects of the soluble receptor on endothelial cell migration,
favoring the interpretation of disruption of endothelial endog-
enous EphA class receptor function by soluble receptors.
Finally, EphA-Fc treatment blocks tyrosine phosphoryla-
tion of endogenous EphA2 receptor relative to control
(Figure 2D), supporting the inhibitory function of soluble
EphA receptors on EphA class signaling.
Our data support the hypothesis that soluble EphA
receptors block endogenous class A Eph ligand–receptor
interaction, thereby affecting recruitment of blood vessels
by tumor cells and inhibiting tumor progression in vivo.
EphA2-Fc treatment inhibits endogenous EphA2 receptor
phosphorylation in islet cell carcinoma relative to control
IgG (Figure 2D), supporting the inhibitory function of soluble
EphA receptors on EphA class signaling. Furthermore,
soluble EphA receptors block tumor-conditioned medium-
induced endothelial cell migration and VEGF-induced angio-
genic responses in vitro (Figure 4). Administration of soluble
EphA receptors in vivo inhibited endothelial cell growth and
survival within the intact tumor (Figure 3). Taken together,
these data suggest that soluble EphA receptors block
endogenous EphA class receptor function on endothelial
cells to inhibit recruitment of new blood vessels by tumors,
thereby suppressing angiogenic islet formation and tumor
progression in multistage carcinogenesis in vivo.
Nevertheless, because the soluble EphA receptor is
administered in vivo, the endothelial cell may not be the only
target, and other cell types may also be involved in the
inhibition of tumor progression by soluble EphA-Fc recep-
tors. One such possible target is the tumor cell. However,
hTC tumor cells do not express significant levels of EphA2
receptor or other class A receptors, as judged by Western
blot analysis, immunohistochemistry, or RNAse protection
assay [9] (Cheng et al., unpublished results). To distinguish
the possibility of a direct effect of tumor cells by soluble
EphA-Fc receptors, we also performed proliferation and
apoptosis assays on cultured hTCs. Our data revealed that
EphA-Fc affects neither cultured hTC tumor cell growth nor
survival (data not shown). Another possible target is inflam-
matory infiltrating cells. Although we have not specifically
looked for changes in macrophages, neutrophils, or mast
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cells in tumor, we do not observe a significant difference in
the total amount of infiltrating cells in H&E–stained tumor
sections between EphA-Fc – and IgG-treated samples.
EphA2 receptor signaling is known to be required for
TNF-a–induced angiogenesis. Pandey et al. [23] showed
that ephrin-A1 is a chemoattractant for endothelial cells
and that ephrin-A1–neutralizing antibodies inhibited TNF-
a–induced cornea angiogenesis. In addition to a role of
ephrin-A1 in TNF-a–induced angiogenesis, here we show
that EphA receptor signaling also plays a role in VEGF-
dependent tumor angiogenesis. Our in vitro studies show
that RIP-Tag tumor cells produce soluble factors that
act upon endothelial cells to induce cell migration. Endo-
thelial migration was inhibited in the presence of either
VEGF-neutralizing antibodies or soluble EphA2 receptor
(Figure 4A). These results indicate that VEGF is a primary
angiogenic factor in the tumor condition medium that induces
cell migration, and soluble EphA2-Fc blocks VEGF-induced
angiogenic response. The role of class A Eph ligand/receptor
function in VEGF-induced angiogenesis is further supported
by in vivo data that administration of soluble EphA receptor
systemically blocks VEGF-induced corneal angiogenesis
(Figure 4B) and VEGF-dependent RIP-Tag angiogenic islet
formation and development of solid islet cell carcinoma
(Figures 1 and 2).
In summary, our findings suggest that class A Eph
receptor regulates tumor angiogenesis and that EphA signal-
ing pathways may represent an attractive novel target for
antiangiogenic therapy in cancer.
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